Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

Safety Information

F112

Sigma-Aldrich

(+)-Fenfluramine hydrochloride

Synonym(s):

(+)-N-Ethyl-α-methyl-m-[trifluoromethyl]phenethylamine hydrochloride, Dexfenfluramine hydrochloride

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C12H16F3N · HCl
CAS Number:
3239-45-0
Molecular Weight:
267.72
EC Number:
221-806-0
MDL number:
MFCD00069276
UNSPSC Code:
12352116
PubChem Substance ID:
24894746
NACRES:
NA.77

form

powder

Quality Level

200

drug control

USDEA Schedule IV

color

white to off-white

solubility

H2O: soluble 10 mg/mL

application(s)

forensics and toxicology

storage temp.

room temp

SMILES string

Cl[H].CCN[C@@H](C)Cc1cccc(c1)C(F)(F)F

InChI

1S/C12H16F3N.ClH/c1-3-16-9(2)7-10-5-4-6-11(8-10)12(13,14)15;/h4-6,8-9,16H,3,7H2,1-2H3;1H/t9-;/m0./s1

InChI key

ZXKXJHAOUFHNAS-FVGYRXGTSA-N

Gene Information

human ... HTR1A(3350) , HTR1B(3351) , HTR1D(3352) , HTR1E(3354) , HTR1F(3355) , HTR2A(3356) , HTR2B(3357) , HTR2C(3358) , HTR3A(3359) , HTR3B(9177) , HTR3C(170572) , HTR3D(200909) , HTR3E(285242) , HTR4(3360) , HTR5A(3361) , HTR6(3362) , HTR7(3363)

Biochem/physiol Actions

(+)-Fenfluramine is a serotonin uptake inhibitor; anoxexic. (+)-Fenfluramine is neurotoxic on prolonged administration or at high dosage. (+)-Fenfluramine releases serotonin from axon terminals by a nonexocytotic mechanism.

Other Notes

Active isomer

Pictograms

Skull and crossbones
GHS06

Signal Word

Danger

Hazard Statements

H301 + H311 + H331

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

JAN Code

F112-BULK:
F112-25MG:
F112-VAR:
F112-8G:
F112-1G:
F112-100MG:

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Delphine Natali et al.
Chest, 140(4), 1066-1068 (2011-10-06)
We report a case of pulmonary arterial hypertension (PAH) occurring in a patient with Cowden syndrome with a mutation in the phosphatase and tensin (PTEN) tumor suppressor gene, in the context of exposure to the appetite suppressant dexfenfluramine. Anorexigen exposure
Margaret R Maclean et al.
Advances in experimental medicine and biology, 661, 309-322 (2010-03-06)
The serotonin hypothesis of pulmonary arterial hypertension (PAH) arose after an outbreak of PAH in patients taking the anorexigenic drugs aminorex and dexfenfluramine. Both of these drugs are serotonin transporter (SERT) substrates and indirect serotinergic agonists. There is now a
Korneel Rabaey et al.
Current opinion in biotechnology, 22(3), 371-377 (2011-03-01)
The production of biofuels and biochemicals is highly electron intensive. To divert fermentative and respiratory pathways to the product of interest, additional electrons (i.e. reducing power) are often needed. Meanwhile, the past decade has seen the breakthrough of sustainable electricity
Rima Hajjo et al.
Journal of medicinal chemistry, 53(21), 7573-7586 (2010-10-21)
Some antipsychotic drugs are known to cause valvular heart disease by activating serotonin 5-HT(2B) receptors. We have developed and validated binary classification QSAR models capable of predicting potential 5-HT(2B) actives. The classification accuracies of the models built to discriminate 5-HT(2B)
Dan Jones
Nature reviews. Drug discovery, 7(12), 961-962 (2008-12-02)
A wave of terminations of development programmes for cannabinoid receptor 1 blockers for obesity indicates the demise of a drug class that was once anticipated to yield blockbusters. Nevertheless, lessons learned might help salvage something for future such approaches.
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service